CVS Health Co. (NYSE:CVS - Free Report) - Stock analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for CVS Health in a research report issued on Thursday, April 24th. Leerink Partnrs analyst M. Cherny now forecasts that the pharmacy operator will post earnings of $1.84 per share for the quarter, up from their prior estimate of $1.62. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for CVS Health's current full-year earnings is $5.89 per share. Leerink Partnrs also issued estimates for CVS Health's Q3 2025 earnings at $1.24 EPS and FY2025 earnings at $5.97 EPS.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%.
Other equities research analysts also recently issued reports about the company. Robert W. Baird lifted their target price on CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 15th. Morgan Stanley reissued an "overweight" rating on shares of CVS Health in a research report on Tuesday, April 15th. Wolfe Research lifted their target price on CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Piper Sandler lifted their price objective on CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a report on Friday, March 21st. Finally, JPMorgan Chase & Co. lifted their price objective on CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a report on Tuesday, February 18th. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $71.83.
Get Our Latest Research Report on CVS
CVS Health Stock Performance
Shares of NYSE:CVS traded up $1.36 on Friday, hitting $66.39. 5,371,474 shares of the company were exchanged, compared to its average volume of 11,811,057. CVS Health has a one year low of $43.56 and a one year high of $71.45. The firm has a market capitalization of $83.70 billion, a price-to-earnings ratio of 18.14, a PEG ratio of 0.98 and a beta of 0.57. The company's 50 day moving average price is $66.45 and its two-hundred day moving average price is $58.74. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81.
CVS Health Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.01%. CVS Health's payout ratio is presently 72.68%.
Insider Activity at CVS Health
In other CVS Health news, Director Michael F. Mahoney purchased 30,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the purchase, the director now owns 39,356 shares of the company's stock, valued at $2,625,045.20. This trade represents a 320.65 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP James David Clark sold 7,513 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. 1.22% of the stock is owned by corporate insiders.
Institutional Trading of CVS Health
Several institutional investors have recently made changes to their positions in the company. Norges Bank bought a new position in CVS Health during the fourth quarter valued at about $839,574,000. Capital World Investors grew its stake in CVS Health by 26.6% in the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after buying an additional 12,819,148 shares in the last quarter. Davis Selected Advisers grew its position in shares of CVS Health by 2,998.1% during the 4th quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator's stock valued at $511,115,000 after purchasing an additional 11,018,438 shares in the last quarter. Dodge & Cox grew its position in shares of CVS Health by 11.2% during the 4th quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after purchasing an additional 7,075,209 shares in the last quarter. Finally, Pzena Investment Management LLC grew its position in CVS Health by 49.3% in the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock worth $880,319,000 after acquiring an additional 6,475,271 shares in the last quarter. Institutional investors own 80.66% of the company's stock.
About CVS Health
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Further Reading
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
